174 related articles for article (PubMed ID: 37256648)
21. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
22. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.
de Sousa LG; Neto FL; Lin J; Ferrarotto R
Curr Oncol Rep; 2022 May; 24(5):621-631. PubMed ID: 35212920
[TBL] [Abstract][Full Text] [Related]
24. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma.
Zhao X; Guo F; Li Z; Jiang P; Deng X; Tian F; Li X; Wang S
Oncol Rep; 2016 Jul; 36(1):419-27. PubMed ID: 27177355
[TBL] [Abstract][Full Text] [Related]
25. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
Yao Y; Ye H; Qi Z; Mo L; Yue Q; Baral A; Hoon DSB; Vera JC; Heiss JD; Chen CC; Zhang J; Jin K; Wang Y; Zang X; Mao Y; Zhou L
Clin Cancer Res; 2016 Jun; 22(11):2778-2790. PubMed ID: 27001312
[TBL] [Abstract][Full Text] [Related]
26. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
[TBL] [Abstract][Full Text] [Related]
27. B7-H4 is a potential prognostic biomarker of prostate cancer.
Li H; Piao L; Liu S; Cui Y; Xuan Y
Exp Mol Pathol; 2020 Jun; 114():104406. PubMed ID: 32088189
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer.
Arigami T; Uenosono Y; Ishigami S; Hagihara T; Haraguchi N; Natsugoe S
World J Surg; 2011 Sep; 35(9):2051-7. PubMed ID: 21748517
[TBL] [Abstract][Full Text] [Related]
29. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
[TBL] [Abstract][Full Text] [Related]
30. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
32. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
33. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
34. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.
Xie N; Cai JB; Zhang L; Zhang PF; Shen YH; Yang X; Lu JC; Gao DM; Kang Q; Liu LX; Zhang C; Huang XY; Zou H; Zhang XY; Song ZJ; Sun HX; Fu BM; Ke AW; Shi GM
Cell Death Dis; 2017 Dec; 8(12):3205. PubMed ID: 29235470
[TBL] [Abstract][Full Text] [Related]
36. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
37. In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type.
Bell D; Bell AH; Bondaruk J; Hanna EY; Weber RS
Cancer; 2016 May; 122(10):1513-22. PubMed ID: 26953815
[TBL] [Abstract][Full Text] [Related]
38. Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma.
Azuma T; Sato Y; Ohno T; Azuma M; Kume H
PLoS One; 2018; 13(7):e0199719. PubMed ID: 30044793
[TBL] [Abstract][Full Text] [Related]
39. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers.
Persson M; Andersson MK; Sahlin PE; Mitani Y; Brandwein-Weber MS; Frierson HF; Moskaluk C; Fonseca I; Ferrarotto R; Boecker W; Loening T; El-Naggar AK; Stenman G
J Pathol; 2023 Nov; 261(3):256-268. PubMed ID: 37565350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
